PF-06838435/ fidanacogene elaparvovec

Phase 3Active

1 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hemophilia B

Conditions

Hemophilia B

Trial Timeline

Jul 29, 2019 → Feb 25, 2031

NCT ID

NCT03861273

About PF-06838435/ fidanacogene elaparvovec

PF-06838435/ fidanacogene elaparvovec is a phase 3 stage product being developed by Pfizer for Hemophilia B. The current trial status is active. This product is registered under clinical trial identifier NCT03861273. Target conditions include Hemophilia B.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia B were approved

Approved (20) Terminated (3) Active (0)

✅EmicizumabRocheApproved

✅BenefixPfizerApproved

✅Nonacog alfaPfizerApproved

✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved

✅Recombinant Factor IX CoagulationPfizerApproved

✅Moroctocog alfa(AF-CC)PfizerApproved

✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03861273	Phase 3	Active	Jul 29, 2019	Feb 25, 2031	Hemophilia B

Competing Products

20 competing products in Hemophilia B

See all competitors

Product	Company	Stage	Hype Score
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab + rFVIIa + aPCC	Chugai Pharmaceutical	Phase 3	40
Human Coagulation Factor VIII	Chugai Pharmaceutical	Phase 3	47
Emicizumab	Chugai Pharmaceutical	Phase 3	47
Emicizumab + Factor VIII (FVIII)	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Roche	Phase 3	40
HEMLIBRA	Johnson & Johnson	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Emicizumab	Roche	Approved	47
Emicizumab	Roche	Phase 3	44
SPK-8011QQ	Roche	Phase 1/2	39
NXT007	Roche	Phase 1/2	39
Emicizumab Injection	Roche	Phase 2	35
Bypassing Agents + FVIII Replacement	Roche	Pre-clinical	26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086	Pfizer	Phase 2	35
Nonacog Alfa (Genetical Recombination)	Pfizer	Pre-clinical	26
Refacto AF	Pfizer	Pre-clinical	18
ReFacto AF	Pfizer	Phase 3	40
Nonacog alfa + Nonacog alfa	Pfizer	Phase 3	40